CABOT CORP CBT
NYSE · XNYS · stock · Miscellaneous Chemical Products
Chart by TradingView
6/9
Piotroski F — financial health
4.38
Altman Z″ — distress risk · safe
29.0%
Dividend payout · safe
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $3.7B | $331.0M | $940.0M | $391.0M | $1.6B |
| 2024 | $4.0B | $380.0M | $960.0M | $451.0M | $1.6B |
| 2023 | $3.9B | $445.0M | $839.0M | $351.0M | $1.4B |
| 2022 | $4.3B | $209.0M | $885.0M | -$111.0M | $1.0B |
| 2021 | $3.4B | $250.0M | $799.0M | $62.0M | $1.1B |
| 2020 | $2.6B | -$238.0M | $500.0M | $177.0M | $814.0M |
Why these scores methodology →
Piotroski F-score: 6/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 4.38 (safe)
- Working capital / assets 0.153
- Retained earnings / assets 0.481
- EBIT / assets 0.163
- Equity / liabilities 0.684
Source: SEC EDGAR filings · CIK 0000016040 · as of 2025-09-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.